Photocure ASA (0IMT) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Photocure Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.132 -- 00:00:04.742 All right, well, welcome to PhotoCure's third quarter 2025 results. 00:00:04.742 -- 00:00:10.751 I'm Dan Schneider, President and CEO, and with me today is Eric Dahl, our CFO. 00:00:11.397 -- 00:00:16.464 A reminder, the usual disclaimers are in effect for today's presentation. 00:00:16.737 -- 00:00:20.603 So I'd like to start with this slide, the strategic priorities and initiatives. 00:00:20.603 -- 00:00:24.510 It's our guide to how we execute and allocate resources across the company. 00:00:24.510 -- 00:00:29.017 At a high level, our strategy is centered around three key pillars, strengthening the 00:00:29.017 -- 00:00:34.626 core HEXFIX SysView business, advancing blue light cystoscopy as a definitive 00:00:34.626 -- 00:00:39.814 standard of care in bladder cancer, and expanding our reach into the broader uro-oncology 00:00:39.814 -- 00:00:42.674 and precision diagnostic space. 00:00:42.674 -- 00:00:46.847 The first pillar, accelerate and expand, is about delivering on our financial guidance 00:00:46.847 -- 00:00:52.123 for disciplined growth in revenue and EBITDA in our core business and to continue generating 00:00:52.123 -- 00:00:56.191 operating leverage, which we continue to do so. 00:00:56.191 -- 00:01:02.059 It's also about driving the blue light cystoscopy mobile strategy for tech in the U.S. 00:01:02.059 -- 00:01:07.387 and increasing penetration in the EU, particularly in the priority growth markets, France, 00:01:07.387 -- 00:01:12.494 Italy, U.K., through blue light expansion and the image upgrades, most recently Viscera 00:01:12.494 -- 00:01:17.562 3 by Olympus. And thirdly, expanding a geographic footprint and 00:01:17.562 -- 00:01:20.440 leveraging our distribution partnerships across the globe. 00:01:20.440 -- 0...